Italia markets open in 6 hours 36 minutes

Lantheus Holdings, Inc. (LNTH)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
78,18+10,79 (+16,01%)
Alla chiusura: 04:00PM EDT
78,29 +0,11 (+0,14%)
Dopo ore: 07:37PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente67,39
Aperto75,00
Denaro78,10 x 600
Lettera78,24 x 300
Min-Max giorno74,82 - 79,25
Intervallo di 52 settimane50,20 - 100,85
Volume3.678.883
Media Volume857.650
Capitalizzazione5,359B
Beta (5 anni mensile)0,54
Rapporto PE (ttm)16,81
EPS (ttm)4,65
Prossima data utili02 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A97,50
  • GlobeNewswire

    Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

    BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria. PYLARIFY AI™ (aPROMI

  • GlobeNewswire

    Lantheus to Present at the Wells Fargo Healthcare Conference

    BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 7. To access a li

  • GlobeNewswire

    Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

    Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readinessBEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the divestiture of its RELISTOR (methylnaltrexone bromid